STRATA Skin Sciences to Participate in the Benchmark Company 13th Annual Discovery Investor Conference
STRATA Skin Sciences (NASDAQ: SSKN), a medical technology company focused on dermatologic treatments, has announced its participation in the Benchmark Company 13th Annual Discovery Investor Conference. The event will take place on Wednesday, December 11, 2024, at the New York Athletic Club in New York City.
Dr. Dolev Rafaeli, President and Chief Executive Officer, will be available for one-on-one meetings with analysts and investors throughout the conference day. Interested attendees can arrange meetings through their Benchmark Company representative, and general conference registration is available online.
STRATA Skin Sciences (NASDAQ: SSKN), un'azienda di tecnologia medica focalizzata sui trattamenti dermatologici, ha annunciato la sua partecipazione alla 13ª Conferenza Annuale Discovery degli Investitori di Benchmark Company. L'evento si svolgerà mercoledì 11 dicembre 2024, presso il New York Athletic Club a New York City.
Il Dr. Dolev Rafaeli, Presidente e Amministratore Delegato, sarà disponibile per incontri one-to-one con analisti e investitori durante tutta la giornata della conferenza. I partecipanti interessati possono organizzare incontri tramite il loro rappresentante di Benchmark Company, e la registrazione generale alla conferenza è disponibile online.
STRATA Skin Sciences (NASDAQ: SSKN), una empresa de tecnología médica enfocada en tratamientos dermatológicos, ha anunciado su participación en la 13ª Conferencia Anual de Inversores Discovery de Benchmark Company. El evento se llevará a cabo el miércoles 11 de diciembre de 2024, en el New York Athletic Club en la ciudad de Nueva York.
El Dr. Dolev Rafaeli, Presidente y Director Ejecutivo, estará disponible para reuniones individuales con analistas e inversores a lo largo del día de la conferencia. Los asistentes interesados pueden coordinar reuniones a través de su representante de Benchmark Company, y la inscripción general a la conferencia está disponible en línea.
STRATA Skin Sciences (NASDAQ: SSKN), 피부 치료에 초점을 맞춘 의료 기술 회사가 Benchmark Company 제13회 연례 Discovery 투자자 회의에 참석한다고 발표했습니다. 이 행사는 2024년 12월 11일 수요일, 뉴욕시의 뉴욕 체육관에서 열릴 예정입니다.
Dr. Dolev Rafaeli, 사장 겸 CEO가 회의 날 동안 애널리스트 및 투자자와의 1:1 미팅을 위해 참석할 예정입니다. 참석자들은 Benchmark Company 대표를 통해 미팅을 조정할 수 있으며, 회의에 대한 일반 등록은 온라인으로 가능합니다.
STRATA Skin Sciences (NASDAQ: SSKN), une entreprise de technologie médicale axée sur les traitements dermatologiques, a annoncé sa participation à la 13ème Conférence Annuelle des Investisseurs Discovery de la Benchmark Company. L'événement aura lieu le mercredi 11 décembre 2024, au New York Athletic Club dans la ville de New York.
Le Dr Dolev Rafaeli, Président et Directeur Général, sera disponible pour des réunions individuelles avec des analystes et des investisseurs tout au long de la journée de la conférence. Les participants intéressés peuvent organiser des réunions par l'intermédiaire de leur représentant de la Benchmark Company, et l'inscription générale pour la conférence est disponible en ligne.
STRATA Skin Sciences (NASDAQ: SSKN), ein Medizintechnikunternehmen, das sich auf dermatologische Behandlungen spezialisiert hat, hat seine Teilnahme an der 13. jährlichen Discovery Investor Conference der Benchmark Company bekannt gegeben. Die Veranstaltung findet am Mittwoch, den 11. Dezember 2024, im New York Athletic Club in New York City statt.
Dr. Dolev Rafaeli, Präsident und Chief Executive Officer, wird während des Konferenztages für Eins-zu-eins-Meetings mit Analysten und Investoren zur Verfügung stehen. Interessierte Teilnehmer können Meetings über ihren Vertreter von Benchmark Company vereinbaren, und die allgemeine Registrierung für die Konferenz ist online verfügbar.
- None.
- None.
HORSHAM, Pa., Dec. 05, 2024 (GLOBE NEWSWIRE) -- STRATA Skin Sciences, Inc. (“STRATA” or the “Company”) (NASDAQ: SSKN), a medical technology company dedicated to developing, commercializing, and marketing innovative products for the treatment of dermatologic conditions, announces that President and Chief Executive Officer Dr. Dolev Rafaeli will participate in the Benchmark Company 13th Annual Discovery Investor Conference that is being held on Wednesday, December 11, 2024, at the New York Athletic Club in New York City.
Dr. Rafaeli will host one-on-one meetings with analysts and investors throughout the day. To schedule a one-on-one meeting with Dr. Rafaeli, attendees should contact their Benchmark Company representative. Investors can attend the conference by registering here.
About STRATA Skin Sciences
STRATA Skin Sciences is a medical technology company dedicated to developing, commercializing, and marketing innovative products for the in-office treatment of various dermatologic conditions, such as psoriasis, vitiligo, and acne. Its products include the XTRAC® excimer laser, VTRAC® lamp systems, and the TheraClear®X Acne Therapy System.
STRATA is proud to offer these exciting technologies in the U.S. through its unique Partnership Program. STRATA’s popular partnership approach includes a fee per treatment cost structure (versus an equipment purchase), installation and use of the device, on-site training for practice personnel, service and maintenance of the equipment, dedicated account and customer service associates, and co-op advertising support to help raise awareness and promote the program within the practice.
Safe Harbor
This press release includes "forward-looking statements" within the meaning of the Securities Litigation Reform Act of 1995. These statements include but are not limited to the Company’s plans, objectives, expectations and intentions and may contain words such as “will,” “may,” “seeks,” and “expects,” that suggest future events or trends. These statements, the Company’s ability to launch and sell products recently acquired or to be developed in the future, the Company’s ability to develop social media marketing campaigns, direct to consumer marketing campaigns, and the Company’s ability to build a leading franchise in dermatology and aesthetics, are based on the Company’s current expectations and are inherently subject to significant uncertainties and changes in circumstances. Actual results may differ materially from the Company’s expectations due to financial, economic, business, competitive, market, regulatory, adverse market conditions labor supply shortages, or supply chain interruptions resulting from fiscal, political factors, international conflicts, responses, or conditions affecting the Company, the medical device industry and our customers and patients in general, as well as more specific risks and uncertainties set forth in the Company’s SEC reports on Forms 10-Q and 10-K. Given such uncertainties, any or all these forward-looking statements may prove to be incorrect or unreliable. The statements in this press release are made as of the date of this press release, even if subsequently made available by the Company on its website or otherwise. The Company does not undertake any obligation to update or revise these statements to reflect events or circumstances occurring after the date of this press release. The Company urges investors to carefully review its SEC disclosures available at www.sec.gov and www.strataskinsciences.com.
Investor Contact:
CORE IR
516-222-2560
IR@strataskin.com
FAQ
When is STRATA Skin Sciences (SSKN) participating in the Benchmark Company Conference?
Where will the Benchmark Company Conference featuring SSKN be held?
How can investors meet with STRATA Skin Sciences (SSKN) at the Benchmark Conference?
What type of meetings will SSKN be conducting at the Benchmark Conference?
